Context Therapeutics Announces First Patient Dosed in the Phase 1 Clinical Trial of CTIM-76
CTIM-76 Phase 1 trial focused on CLDN6-positive gynecologic and testicular cancers Trial marks key milestone in driving ...
Business Insider12d
Context Therapeutics Appoints Andy Pasternak as Chairman of the Board of Directors
Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a biopharmaceutical company advancing T cell engagers for solid tumors, today announced the appointment of Andy Pasternak as ...
Context Therapeutics Inc. (NASDAQ:CNTX) Given Consensus Rating of “Buy” by Analysts
Shares of Context Therapeutics Inc. (NASDAQ:CNTX – Get Free Report) have earned a consensus rating of “Buy” from the seven brokerages that are covering the stock, MarketBeat.com reports. Six research ...
Nasdaq10d
Context Therapeutics Doses First Patient in Phase 1 Trial of CTIM-76 for CLDN6-Positive Cancers
Context Therapeutics announces first patient dosed in Phase 1 trial of CTIM-76 for CLDN6-positive cancers. Initial data expected 2026. Context Therapeutics Inc. has announced the dosing of the ...
Morningstar10d
Context Therapeutics Announces First Patient Dosed in the Phase 1 Clinical Trial of CTIM-76
PHILADELPHIA, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a biopharmaceutical company advancing T cell engagers for solid ...
Yahoo Finance12d
Context Therapeutics Appoints Andy Pasternak as Chairman of the Board of Directors
PHILADELPHIA, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a biopharmaceutical company advancing T cell engagers for solid ...
Stockhouse11d
Context Therapeutics Appoints Andy Pasternak as Chairman of the Board of Directors
PHILADELPHIA, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a biopharmaceutical company advancing ...